Enzolytics Attempts To Hit $1 Mark After Discovering Seven Immutable Sites On HIV

Treating COVID-19 and HIV patients became even a burden to biotech companies as the viruses are complicated to neutralize and eliminate. By developing antibodies for HIV treatment Enzolytics (OTC: ENZC) has recently found seven conserved target sites on the HIV virus so it could be easier to suit antibodies for each identified area.


Yesterday ENZC shares popped over 25% right after the announcement. So even today the stock is full of confidence to gain more points, maybe, around 30% it can soar if big whales pay attention swiftly. Right now about 12 million shares are being traded by increasing the demand for each possibly golden egg generating ENZC share.

Who knows that Enzolytics will find the most optimal antibodies for both HIV and SARS-COV-2? Everything changes so quickly this year as the territory of competition is wider and rich in creative biotech talents. An optimistic shareholder of ENZC may surely say that $1 line is possible to cross this year.

AdobeStock 117911056

Emile Ortega

Editor and Computer Expert A hardcore tech enthusiast and computer expert Uson Abdilazhanov who holds a degree in communications started writing in his personal blogs since 2012. That time he was interested in the technical part of the computer. But now the software aspect plays an important role in his career. Currently, he runs a PC building and repairing shop which helps a lot of designers and gamers who always like to try new things.

Emile Ortega has 529 posts and counting. See all posts by Emile Ortega